Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 14, 2014; 20(38): 13705-13717
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13705
Figure 13
Figure 13 Quantification of ribonuclease protection assay of endogenous 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 mRNA expression in pancreatic carcinoma cell line Panc1, stable transfected by pcDNA3. 1(+) vector or dominant/negative 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 in normoxic (control) condition (C) and after treatment of Panc1 cells with dimethyloxalylglycine, inhibitor of prolyl hydroxylase (I). n = 5; bP < 0.01 vs control[89]. dnPFKFB-3: Dominant/negative 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3.